Search results for: Innovation Policy Prize
Filter search results
Spotlight on OHE: Value Based Pricing and New Technologies
31 December 2012
…Towse participated in a workshop organised by The Centre for Innovation in Regulatory Science (CIRS) that focused on companion diagnostics. His session focused on whether companion diagnostics will become the…
R&D Cost Drivers to be Explained by OHE Expert
18 January 2013
Jorge Mestre-Ferrandiz, lead author on OHE’s recent report on the cost of developing new drugs, will be discussing the important cost drivers at an upcoming UCL Vision seminar in London…
Changes in Determining Medicines Pricing in France, Germany and the UK
24 January 2013
…(VBP) is about the weighting given to the evidence and the social value of a drug. Overall, emphasis is increasing on “proving” innovation and/or an additional health benefit for a…
New OHE Study Compares Decisions by Five HTA Agencies on Oncology Meds
31 January 2013
Just out in the International Journal of Technology Assessment in Health Care is an important new study that reviews appraisals of breast cancer and colorectal cancer medicines by HTA agencies…
OHE responds to the King’s Speech and the proposed NHS Modernisation Bill
13 May 2026
…But the careful and considered use of private financing for infrastructure investment, blended finance and social impact bonds for prevention, and the adoption of innovation from the private sector should…
Angus Macfarlane
29 October 2025
…context. His research interests include the economic evaluation of infectious disease interventions, the value of novel health technologies, and the role of innovation in improving health system efficiency and outcomes….
Henry Fong
2 October 2024
…York. His master’s dissertation focused on the economic evaluation of a digital health application for periodontitis in Germany. Henry is interested in understanding the value of pharmaceutical innovations and decision-making…
Around The World in HTAs: Greece – Late but with an Optimistic Future
18 October 2023
…are still a few concerns regarding its structure, the assessment criteria in its clinical parameters, and the prioritization of medicines based on specific parameters such as degree of innovation. There…
Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectiveness Evaluations
25 August 2015
A Research Paper on the topic of incorporating life-cycle price modelling into pharmaceutical cost-effectiveness evaluations has just been published by OHE. Why might the launch price of a new drug…